Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia

Serrao, Alessandra; Ballotta, Laura; Dragoni, Francesco; Pallotta, Agnese; Chistolini, Antonio

doi:10.1016/j.thromres.2020.10.020

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study conducted on a cohort of 209 patients aimed to evaluate the benefits of DOACs for secondary prophylaxis of TEV in patients diagnosed with thrombophilia compared to a group without this underlying pathology. Following a 20-month follow-up period, the study findings revealed no statistically significant differences in safety and efficacy outcomes between full-dose and reduced-dose DOAC regimens [28]. Thus, in this patient's case, the decision was made to continue the treatment using apixaban at a dosage of 2.5 mg twice daily and double antiaggregant treatment for the first six months after the MI.…”

Section: Discussionmentioning

confidence: 83%

Challenges of a Patient with Thromboembolism

Oancea,

Maștaleru,

Abdulan

et al. 2023

Reports

View full text Add to dashboard Cite

Background: FV Leiden is an autosomal dominant disease, representing one of the most prevalent genetic causes for hereditary thrombophilia manifested by venous thromboembolism. Methods: We report a case of a 30-year-old patient who was admitted for enrollment in phase II cardiac rehabilitation. The cardiovascular disease onset was five years ago when the patient was diagnosed with superficial vein thrombosis, for which anticoagulant treatment was recommended. However, he discontinued the prescribed treatment independently, which resulted in the development of deep vein thrombosis. A screening for risk factors associated with venous thromboembolism was conducted, leading to the identification of a heterozygous mutation of factor V Leiden. Later, the patient was hospitalized for acute coronary syndrome necessitating stent implantation. Following this procedure, the patient started a cardiac rehabilitation program, where the patient received multidisciplinary counseling. Conclusions: At the end of the cardiac rehab, significant improvements were observed in clinical and hemodynamic parameters. Consequently, the patient was advised to continue rehabilitation treatment in the outpatient setting. Also, for patients with suboptimal maintenance of the therapeutic range of INR, the use of apixaban might be considered. Furthermore, the utilization of a reduced dosage of apixaban has demonstrated its effectiveness in preventing further venous thromboembolism.

show abstract

Section: Discussionmentioning

confidence: 83%